From the Department of Obstetrics and Gynecology, Washington University in St Louis, St Louis, Missouri.
Obstet Gynecol. 2011 Jun;117(6):1341-1348. doi: 10.1097/AOG.0b013e31821aa739.
To estimate if echogenic bowel diagnosed on second-trimester ultrasonography has an independent risk association with intrauterine growth restriction (IUGR) and intrauterine fetal demise.
This is a retrospective cohort study of all patients with singleton gestations who presented to our institution for second-trimester ultrasonography between 1990 and 2008. Study groups were defined by the presence or absence of echogenic bowel. Primary outcomes were IUGR, defined as birth weight less than the 10th percentile for gestational age and intrauterine fetal demise at 20 weeks or more of gestation. Univariable and multivariable logistic regression analyses were used to estimate the risk of intrauterine fetal demise and IUGR in fetuses with echogenic bowel. Analyses were repeated after excluding cases of aneuploidy, cytomegalovirus (CMV) infection, other major congenital anomalies, and abnormal second-trimester serum screening results.
Of 64,048 patients, the incidence of echogenic bowel was 0.4%. Of these, echogenic bowel was an isolated finding in 188 (72.3%) cases. There were 579 (0.9%) cases of intrauterine fetal demise and 8,173 (12.8%) cases of IUGR in the entire cohort. After excluding cases of aneuploidy and CMV infection, the incidence of intrauterine fetal demise was 7.3% in the echogenic bowel group compared with 0.9% in the nonechogenic bowel group, translating to an absolute risk increase of 6.4%. The incidence of IUGR in the echogenic bowel group was 19.5% compared with 12.9% in the nonechogenic bowel group (absolute risk increase, 6.6%). After controlling for potential confounders, echogenic bowel was significantly associated with both intrauterine fetal demise (adjusted odds ratio [OR] 9.6, 95% confidence interval [CI] 5.8-15.9) and IUGR (adjusted OR 2.1, 95% CI 1.5-2.9). This risk association remained significant even when evaluating echogenic bowel as an isolated sonographic finding.
The presence of echogenic bowel on ultrasonography is independently associated with an increased risk for both IUGR and intrauterine fetal demise. Serial growth assessment and antenatal testing may be warranted in these patients.
评估中孕期超声检查发现的肠回声增强是否与胎儿生长受限(IUGR)和宫内胎儿死亡有独立的风险关联。
这是一项对 1990 年至 2008 年期间在我院行中孕期超声检查的所有单胎妊娠患者进行的回顾性队列研究。研究组根据是否存在肠回声增强进行定义。主要结局为 IUGR,定义为出生体重低于相应胎龄第 10 百分位数和 20 周或以上胎死宫内。采用单变量和多变量逻辑回归分析评估肠回声增强胎儿发生宫内胎儿死亡和 IUGR 的风险。在排除了非整倍体、巨细胞病毒(CMV)感染、其他主要先天性异常和异常中孕期血清筛查结果后,重复了分析。
在 64048 例患者中,肠回声增强的发生率为 0.4%。其中,188 例(72.3%)为孤立性肠回声增强。整个队列中,宫内胎儿死亡 579 例(0.9%),IUGR8173 例(12.8%)。排除非整倍体和 CMV 感染后,肠回声增强组的宫内胎儿死亡发生率为 7.3%,而非肠回声增强组为 0.9%,绝对风险增加 6.4%。肠回声增强组的 IUGR 发生率为 19.5%,而非肠回声增强组为 12.9%(绝对风险增加 6.6%)。在控制潜在混杂因素后,肠回声增强与宫内胎儿死亡(校正比值比[OR]9.6,95%置信区间[CI]5.8-15.9)和 IUGR(校正 OR 2.1,95% CI 1.5-2.9)均显著相关。即使将肠回声增强视为孤立的超声发现进行评估,这种风险关联仍然显著。
超声检查发现肠回声增强与 IUGR 和宫内胎儿死亡的风险增加独立相关。这些患者可能需要进行连续生长评估和产前检查。